A new paper finds one reason for the silence – a single protein inside the cells that appears to push them to give up.
The plan was to disable each one in turn and watch what its loss did to the engineered cells.
In mouse after mouse, the engineered cells held tumors in check for longer and the animals showed improved survival.
Furthermore, gains showed up across different tumor types and different versions of the engineered cells.
Switching it off kept the engineered cells potent far longer in animals – a link no one had drawn to this protein before.
Engineered immune cells have cleared leukemias that resisted every other treatment. Doctors take a patient’s T cells, give them a new receptor that hunts cancer, and return them to the body. In some blood cancers, the cells drive disease into full remission.
Aimed at solid tumors in organs like the lung or pancreas, the same cells go quiet within weeks. A new paper finds one reason for the silence – a single protein inside the cells that appears to push them to give up.
That stalling has a name. Scientists call it T-cell exhaustion – the slow fade that creeps in when immune cells fight a tumor for too long, until they stop dividing and stop signaling for the attack. A deep review has tracked this burnout for years.
The off switch in T cells
Pinning the blame on one gene meant testing hundreds at once. An international team led by Professor Michel Sadelain, M.D., Ph.D., of Columbia University in New York, took on that job, working with researchers at University Hospital Tübingen in Germany.
Their search zeroed in on roughly 400 transcription factors – proteins that turn other genes on or off. The plan was to disable each one in turn and watch what its loss did to the engineered cells.
What set the effort apart was where the testing happened. Most screens like this run only in a dish. Not this one. The team also pushed the cells into living mice and watched them work for weeks under relentless pressure.
A protein named NFIL3
One name kept climbing the list. The screens flagged NFIL3 – a protein that no one had pegged as a ringleader of exhaustion – as the strongest link to cells losing their fight.
Professor Judith Feucht, M.D., of University Hospital Tübingen, helped lead the work alongside Sadelain. In the cells they studied, NFIL3 appeared to push T cells toward that worn-out state, though exactly how is still being worked out.
“We expect this to open up new possibilities in the treatment of cancer patients,” said Feucht. Switching off the protein could be a possible turning point for how long the T-cell therapy can keep working.
T cells keep fighting
To shut the gene down, the team reached for CRISPR, the editing tool that finds a chosen stretch of DNA and cuts it out. With NFIL3 gone, the cells behaved like a wholly different population. They were tougher. Slower to quit.
The altered cells kept multiplying instead of petering out. They pumped out more of the signals that drive an immune assault, and they resisted hardening into the spent, end-stage form that marks an exhausted cell.
In mouse after mouse, the engineered cells held tumors in check for longer and the animals showed improved survival.
Furthermore, gains showed up across different tumor types and different versions of the engineered cells. All in animals, not people – a line the researchers refuse to blur.
Testing inside the body
Testing inside living animals was no small detail. A gene that looks harmless in a lab dish can act very differently once cells hit the low oxygen, scarce fuel, and constant signaling of a real tumor.
For years, scientists have copied that wear in dish setups that batter the cells with repeated stimulation, an approach laid out in one widely used study.
Useful as they are, such tests miss what only surfaces inside a living body can reveal.
Running both tests together is what let the team trust the answer. Under steady pressure, the NFIL3-free cells settled into a gene-activity pattern that, in earlier patients, had lined up with stronger responses to treatment.
A growing suspect list
NFIL3 is not the first gene caught dragging T cells down. A much-cited paper had already tied the worn-out state to another master-switch protein, and other suspects have come up since.
What sets this one apart is both the culprit and the method. A fresh name on the list, and a tougher way of catching it. Few teams had run this kind of hunt inside living animals rather than in a dish.
Disabling NFIL3 did not hinge on one tumor type or one cell design. In addition, the boost showed up across blood cancers and solid ones alike, which is part of why the finding has drawn such close attention.
What could change now
A single gene-regulating protein, NFIL3, helps drive the exhaustion that has long blunted these therapies.
Switching it off kept the engineered cells potent far longer in animals – a link no one had drawn to this protein before.
That hands cell engineers a concrete target. Build the next therapies with NFIL3 switched off, the reasoning goes, and the cells might last long enough to wear down the solid tumors that make up most human cancers.
The jump from mice to people still lies ahead, and clinical trials will tell whether the move pays off in humans. What’s changed is direction.
Researchers know which protein to target now – and it was one that nobody had been watching.
The study is published in Cancer Discovery.
—–
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap , a free app brought to you by Eric Ralls and Earth.com.
—–
